Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Insider Monkey12-17

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492095678?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/39AH7zjtXsp7nKD7wJ7R9A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45","is_english":true,"pubTime":"2024-12-17 19:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492095678","market":"us","top_or_hot":-1,"title":"Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-inc-amgn-best-weight-115603628.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 19:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amgen-inc-amgn-best-weight-115603628.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-inc-amgn-best-weight-115603628.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1074936037.SGD","symbol_name":"JPMorgan Funds - US Value A (acc) SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/amgen-inc-amgn-best-weight-115603628.html","article_id":"2492095678","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/39AH7zjtXsp7nKD7wJ7R9A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492095678","pubTimestamp":1734436563,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds.In this article, we are going to take a look at where Amgen Inc.  stands against the other weight loss stocks.The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications. Given this increase in demand, Morgan Stanley Research has raised its forecast for the worldwide obesity medication market from $77 billion to $105 billion by 2030. Branded obesity medications brought approximately $6 billion in 2023.By 2030, the GLP-1 market is expected to grow to $100 billion, driven equally by obesity and diabetes, according to JP Morgan Research. Thirty million GLP-1 users, or around 9% of the population, may be in the US by 2030. The rising demand for obesity drugs will have a broad effect, helping industries like biotech but creating challenges for others like the food and beverage industry.According to Chris Schott, a Senior Analyst specializing in the U.S. Diversified Biopha","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","USAW.SI":"AMZN 3xLongSG261006","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","TSYW.SI":"TESLA 3xLongSG261006","QID":"纳指两倍做空ETF","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC",".IXIC":"NASDAQ Composite","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4516":"特朗普概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","AMGN":"安进","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","PSQ":"纳指反向ETF","BK4566":"资本集团","QLD":"纳指两倍做多ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","NVIW.SI":"NVDA 3xLongSG261006","USJW.SI":"ALPHAB 3xLongSG261006","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0106831901.USD":"贝莱德世界金融基金A2","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"根据对冲基金的说法，安进公司（AMGN）是现在最值得购买的减肥股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,".IXIC":0.9,"USJW.SI":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other weight loss stocks.\nThe Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications\nMost people have at some point sought to include weight loss and physical exercise in their daily life. The weight loss and fitness market is quite substantial worldwide since improving one's fitness can have direct physical and psychological benefits. Over one billion people worldwide—650 million adults, 340 million adolescents, and 39 million children—are obese, according to the WHO. A novel class of weight-loss medications that don't include strict exercise regimens or diets seems to be revolutionary. People who are overweight or obese can lose 15% to 20% of their body weight with the aid of these ground-breaking medications. According to Andy Acker, portfolio manager at Janus Henderson Investors, \"This may be the largest opportunity we've ever seen in the pharmaceutical industry.\" Weight-loss medications are undoubtedly well-liked. Investors are drawing comparisons between the leader in artificial intelligence chips and the US pioneer in weight-loss drugs.\nGiven this increase in demand, Morgan Stanley Research has raised its forecast for the worldwide obesity medication market from $77 billion to $105 billion by 2030. Branded obesity medications brought approximately $6 billion in 2023.\nAccording to Forbes, the most prescribed Glucagon-Like Peptide-1 GLP-1 agonist in 2023 was Semaglutide, the market leader for obesity medications and the generic form of Ozempic, Wegovy, and Rybelsus. It accounted for almost 88% of all new prescriptions. At present, the FDA has approved just three GLP-1 medications for weight control: tirzepatide, liraglutide, and semaglutide.\nBy 2030, the GLP-1 market is expected to grow to $100 billion, driven equally by obesity and diabetes, according to JP Morgan Research. Thirty million GLP-1 users, or around 9% of the population, may be in the US by 2030. The rising demand for obesity drugs will have a broad effect, helping industries like biotech but creating challenges for others like the food and beverage industry.\nAccording to Chris Schott, a Senior Analyst specializing in the U.S. Diversified Biopharma industry,\n\n“GLP-1s have been used to treat T2D since 2005, starting with the approval of Byetta, with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer significant advantages over previous products and have accelerated class growth,” “Indeed, the newest generations of GLP-1s and combos lead to 15-25+% weight loss on average, well above prior generations of products.”\n\nSome are praising the most recent generation of GLP-1 pharmaceuticals as \"miracle drugs\" for the treatment of obesity. However, because GLP-1s are expensive and have limited insurance coverage, not all obese people can use them. According to Jonathan Gruber, a professor of economics and the chairman of MIT's economics department, the annual cost of treating 40% of obese Americans at the current rate—roughly $15,000 per person—would surpass $1 trillion. That's almost the same as the government spends on the entire Medicare program. That's a staggering figure.\nGLP-1 Medications: Balancing Rising Demand, Shortages, and Market Potential\nAccording to a study released in the Annals of Internal Medicine, the use of GLP-1 medications, including semaglutide, for weight loss has increased over the last ten years, while it has dropped by about 10% among those with type 2 diabetes. The researchers warn that the ensuing extended drug scarcity may limit the treatments' availability to diabetics. Dr. Yee Hui Yeo, a clinical fellow in Cedars-Sina's Karsh Division of Gastroenterology and Hepatology, emphasized that it is crucial to ensure that diabetic patients have access to GLP-1 therapies as the demand for obesity medications increases.\nAccording to the FDA, growing demand is the cause of the shortages. The European Medicines Agency warned that the GLP-1 medicine shortage is a \"major public health concern\" that is unlikely to be resolved in 2024, indicating that the shortages affect more than only the US. According to NPR, shortages have made it difficult for those with diabetes to get their prescriptions, and some have had to reduce the medications they can use.\nThe potential of GLP-1 medications, which were first created to treat diabetes but are currently being used to treat obesity, was covered by the panelists on \"Weighing the Future of Obesity Drugs,\" which included Julia Angeles of Baillie Gifford, Debra Netschert of Jennison Investments, and Gentry Lee of Fayez Serofim. Netschert highlighted ongoing efforts to further reduce injection frequency and minimize adverse responses, as well as the development of GLP-1 medicine delivery from weekly dosages to multiple daily injections. Despite their exceptional efficacy, Netschert noted that due to supply limits, 1.5 million of the 110 million eligible patients in the US are now receiving therapy with GLP-1 medications. In their disagreement over who should foot the bill, Netschert pointed to significant insurance and Medicare/Medicaid reimbursements, while Angeles asserted that most patients pay cash. According to Netschert, up to 700 million people globally might require these medications outside of American borders. Notably, the panel found that GLP-1 medications were approved more quickly in the United Kingdom than in any other country, indicating their perceived value. The UK payors are generally stringent.\nSince the market for obesity medications is still in its infancy, it would be a good idea to add several weight reduction stocks to your watchlists.\nOur Methodology \nFor this list, we scanned through holdings of weight loss ETFs and online rankings to form an initial list of 20 weight loss stocks. From that list, we picked 12 stocks with the highest number of hedge fund holders as of Q3 2024, based on data tracked by the Insider Monkey database. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A pharmacist filling a prescription for a complex drug developed by the company. \nAmgen Inc. (NASDAQ:AMGN)\nNumber of Hedge Fund Holders: 68 \nAmgen Inc. (NASDAQ:AMGN) is a biotechnology company that develops innovative human medicines for serious diseases, including cancer, cardiovascular conditions, and neurological disorders. It produces biological therapies like Neupogen, Neulasta, Epogen, and Enbrel. Recently, the company has expanded into the GLP-1 weight loss market with drugs such as MariTide and AMG 133, focusing on advancing treatments for weight management.\nAmgen Inc. (NASDAQ:AMGN)'s MariTide activates the GLP-1 hormone, promoting fullness, while blocking the GIP hormone, which regulates fat storage and metabolism. Unlike other weight loss medications, MariTide is administered once a month via subcutaneous injection, improving convenience and patient compliance. In clinical trials, MariTide showed promising results. In Phase 1, participants lost an average of 14.5% of their body weight over 12 weeks. In Phase 2, non-diabetic participants lost up to 20% of their weight, while those with Type 2 diabetes lost up to 17% and saw significant improvements in glycemic control.\nIn the third quarter of 2024, Amgen Inc. (NASDAQ:AMGN) reported a 23% increase in total revenues, reaching $8.5 billion, driven by strong product sales growth, particularly from Tezspire, which saw a 67% increase, and Repatha, which grew by 40%. The corporation achieved an operating margin of 49.6%, demonstrating efficient management despite rising operational costs. Free cash flow totaled $3.3 billion, while R&D spending rose by 35% to $1.4 billion. SG&A expenses increased by 21% year-over-year, and the non-GAAP tax rate dropped to 13.4% which reflected favorable changes in the earnings mix. Additionally, Amgen Inc. (NASDAQ:AMGN) retired $2.5 billion in debt, strengthening its balance sheet and financial position.\nOverall AMGN ranks 4th on our list of the best weight loss stocks to buy according to hedge funds. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than AMGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock   \nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492095678"}